LINEAGE CELL THERAPEUTICS INC (LCTX) — insider trading
Health Care · NYSE American
LINEAGE CELL THERAPEUTICS INC (LCTX) has 16 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase among the most recent 16 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Amin Dipti | Director | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Russell Angus C. | Director | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | ANDREWS DEBORAH J | Director | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Mulroy Michael H. | Director | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Jayasuriya Anula | Director | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Bradsher Neal C | Director, 10% owner | Grant / award / vesting (derivative) | 125,000 | $0.00 | $0 | Form 4 |
| 2026-03-12 | Culley Brian M | Director, Officer (President and CEO) | Open-market purchase | 15,000 | $1.63 | $24.4K | Form 4 |
| 2026-03-05 | Samuel George A. III | Officer (General Counsel and Secretary) | Grant / award / vesting (derivative) | 900,000 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Howe Jill Ann | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 1,050,000 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Culley Brian M | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 3,250,000 | $0.00 | $0 | Form 4 |
| 2026-02-11 | Samuel George A. III | Officer (General Counsel and Secretary) | Option exercise / conversion (derivative) | 6,075 | $0.00 | $0 | Form 4 |
| 2026-02-11 | Samuel George A. III | Officer (General Counsel and Secretary) | Shares withheld for taxes / exercise cost | 2,502 | $1.80 | $4.5K | Form 4 |
| 2026-02-11 | Samuel George A. III | Officer (General Counsel and Secretary) | Option exercise / conversion | 6,075 | — | — | Form 4 |
| 2026-02-11 | Culley Brian M | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 31,250 | $0.00 | $0 | Form 4 |
| 2026-02-11 | Culley Brian M | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 12,869 | $1.80 | $23.2K | Form 4 |
| 2026-02-11 | Culley Brian M | Director, Officer (President and CEO) | Option exercise / conversion | 31,250 | — | — | Form 4 |
Ask the chat about LCTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LINEAGE CELL THERAPEUTICS INC (LCTX).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.